| Acquired by | AstraZeneca |
| Price | $1.15B |
| Date | 6/13 |
| Website | pearltherapeutics... |
| Category | BioTech |
| Phone | 650-305-2600 |
| Employees | |
| Founded | 2006 |
| Description | Respiratory Disease research |
| TOTAL | $167M |
| FUNDING TOTAL | $167M |
| Series A, 7/08 Clarus Ventures New Leaf Venture Partners 5AM Ventures Nektar Therapeutics | $18M |
| Series C, 3/10 Clarus Ventures New Leaf Venture Partners 5AM Ventures | $15M |
| Series C, 10/10 New Leaf Venture Partners 5AM Ventures Vatera Healthcare Partners | $69M |
| Series D, 11/12 Vatera Healthcare Partners 5AM Ventures Clarus Ventures New Leaf Venture Partners | $65M |
Pearl Therapeutics is developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases, including chronic obstructive pulmonary disease.
Pearl’s current focus is on making advanced inhaled therapies available to broad patient populations via familiar and accepted metered dose inhalers.
Pearl is a privately held company led by a seasoned team of respiratory product development experts. Pearl aims to offer patients and healthcare providers alternatives that better meet their needs and improve upon the safety and efficacy of existing respiratory therapeutics to achieve better clinical outcomes.
